Organigram Global Inc. (OGI) 股票分析

公司概述

Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products within the Canadian market, offering a comprehensive portfolio that includes medical cannabis such as whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and concentrates, alongside adult-use recreational cannabis. The company operates within the Healthcare sector, specifically categorized under the industry of Drug Manufacturers - Specialty & Generic, which typically involves the development and commercialization of specialized pharmaceutical or therapeutic compounds distinct from mass-market generics. Organigram Global Inc. currently holds a market capitalization of $180.64M, reports annual revenue of $279.99M based on trailing twelve months data, and employs a workforce of 1137 individuals. The combination of a market cap under $200 million and revenue approaching $280 million suggests the company is a mid-sized enterprise that has achieved significant scale in a niche sector but remains relatively small compared to large-cap pharmaceutical peers, indicating a position that is likely sensitive to regulatory shifts and specific market demand fluctuations.

财务健康

The company reported revenue of $279.99M over the trailing twelve months, with net income of $18.17M and an EBITDA of $5.43M, revealing a cost structure where operating expenses significantly erode the bottom line despite a healthy gross profit generation. The reported free cash flow stands at -$39,607,124, which indicates that the company is currently burning cash, likely due to heavy capital expenditures or working capital requirements associated with expanding production and distribution networks in the cannabis space. Organigram Global Inc. maintains a gross margin of 35.6%, reflecting the pricing power and production efficiency in its primary product lines, while an operating margin of -5.4% highlights that operating costs exceed operating income, and a profit margin of 6.5% demonstrates that the company remains profitable on a bottom-line basis. The balance sheet shows cash holdings of $8.38M against total debt of $8.45M, resulting in a debt-to-equity ratio of 1.99, which signifies a leveraged financial structure where the company's liabilities are nearly equal to its equity base. A current ratio of 2.73 suggests that the company possesses sufficient current assets to cover its short-term liabilities more than twice over, indicating robust short-term liquidity management despite the negative operating cash flow. Return on Equity stands at 4.6% while Return on Assets is -1.5%, revealing that management is generating modest returns for shareholders but is currently destroying value relative to the total asset base due to high operational leverage or inefficiencies in asset utilization.

估值评估

The trailing twelve months P/E ratio is 11.91, whereas the forward P/E is 72.78, implying a stark divergence where the market prices in significantly higher future earnings expectations that are not yet reflected in current profitability. The price-to-book ratio is 0.67, indicating that the stock trades at a discount to its book value, suggesting the market may be undervaluing the company's tangible assets or anticipating future earnings challenges. Alternative valuation metrics include a price-to-sales ratio of 0.65 and an EV/EBITDA of 42.72, which collectively suggest the market values the company based on sales revenue rather than current earnings, potentially reflecting skepticism about the sustainability of current profit margins or the high cost of growth. The 52-week high is $2.24 and the 52-week low is $0.85, and without the current stock price explicitly provided in the source facts, the absolute percentage deviation cannot be calculated; however, the wide trading range of $1.39 between the high and low underscores significant intrayear volatility. The beta value is 1.93, meaning the stock price is expected to be nearly twice as volatile as the broader market, exposing investors to substantial price swings that correlate strongly with sector-specific sentiment rather than general market movements.

Growth & Income

Revenue growth year-over-year is 48.7%, while earnings growth year-over-year is listed as N/A, indicating that revenue expansion is currently outpacing any measurable earnings growth due to the absence of consistent historical earnings data or significant one-time costs impacting comparability. As the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, which means the organization retains all of its net income to reinvest into operations, research, or market expansion rather than distributing cash to shareholders. The absence of a dividend payout ratio eliminates concerns regarding dividend sustainability, as the company prioritizes capital allocation for organic growth initiatives within the competitive cannabis manufacturing landscape. Overall, the company presents a high-growth profile characterized by substantial revenue expansion and a reinvestment strategy, though the lack of earnings growth metrics and negative free cash flow suggests that profitability is still in a transitional phase.